Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase I Multi-Cohort Trial of Pembrolizumab (MK-3475) in Combination with Backbone Treatments for Subjects with Multiple Myeloma.

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell, Little Silver

Sponsor
Merck

Protocol Number
3475-023 KEYNOTE

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase I Multi-Cohort Trial of Pembrolizumab (MK-3475) in Combination with Backbone Treatments for Subjects with Multiple Myeloma.

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell, Little Silver

Sponsor
Merck

Protocol Number
3475-023 KEYNOTE

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase I Multi-Cohort Trial of Pembrolizumab (MK-3475) in Combination with Backbone Treatments for Subjects with Multiple Myeloma.

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell, Little Silver

Sponsor
Merck

Protocol Number
3475-023 KEYNOTE

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase I Multi-Cohort Trial of Pembrolizumab (MK-3475) in Combination with Backbone Treatments for Subjects with Multiple Myeloma.

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell, Little Silver

Sponsor
Merck

Protocol Number
3475-023 KEYNOTE

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase I Multi-Cohort Trial of Pembrolizumab (MK-3475) in Combination with Backbone Treatments for Subjects with Multiple Myeloma.

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell, Little Silver

Sponsor
Merck

Protocol Number
3475-023 KEYNOTE

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase I Multi-Cohort Trial of Pembrolizumab (MK-3475) in Combination with Backbone Treatments for Subjects with Multiple Myeloma.

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell, Little Silver

Sponsor
Merck

Protocol Number
3475-023 KEYNOTE

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase I Multi-Cohort Trial of Pembrolizumab (MK-3475) in Combination with Backbone Treatments for Subjects with Multiple Myeloma.

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell, Little Silver

Sponsor
Merck

Protocol Number
3475-023 KEYNOTE

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase I Multi-Cohort Trial of Pembrolizumab (MK-3475) in Combination with Backbone Treatments for Subjects with Multiple Myeloma.

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell, Little Silver

Sponsor
Merck

Protocol Number
3475-023 KEYNOTE

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase I Multi-Cohort Trial of Pembrolizumab (MK-3475) in Combination with Backbone Treatments for Subjects with Multiple Myeloma.

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell, Little Silver

Sponsor
Merck

Protocol Number
3475-023 KEYNOTE

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase I Multi-Cohort Trial of Pembrolizumab (MK-3475) in Combination with Backbone Treatments for Subjects with Multiple Myeloma.

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell, Little Silver

Sponsor
Merck

Protocol Number
3475-023 KEYNOTE

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase I Multi-Cohort Trial of Pembrolizumab (MK-3475) in Combination with Backbone Treatments for Subjects with Multiple Myeloma.

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell, Little Silver

Sponsor
Merck

Protocol Number
3475-023 KEYNOTE

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase I Multi-Cohort Trial of Pembrolizumab (MK-3475) in Combination with Backbone Treatments for Subjects with Multiple Myeloma.

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell, Little Silver

Sponsor
Merck

Protocol Number
3475-023 KEYNOTE

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase I Multi-Cohort Trial of Pembrolizumab (MK-3475) in Combination with Backbone Treatments for Subjects with Multiple Myeloma.

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell, Little Silver

Sponsor
Merck

Protocol Number
3475-023 KEYNOTE

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase I Multi-Cohort Trial of Pembrolizumab (MK-3475) in Combination with Backbone Treatments for Subjects with Multiple Myeloma.

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell, Little Silver

Sponsor
Merck

Protocol Number
3475-023 KEYNOTE

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase I Multi-Cohort Trial of Pembrolizumab (MK-3475) in Combination with Backbone Treatments for Subjects with Multiple Myeloma.

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell, Little Silver

Sponsor
Merck

Protocol Number
3475-023 KEYNOTE

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase I Multi-Cohort Trial of Pembrolizumab (MK-3475) in Combination with Backbone Treatments for Subjects with Multiple Myeloma.

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell, Little Silver

Sponsor
Merck

Protocol Number
3475-023 KEYNOTE

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase I Multi-Cohort Trial of Pembrolizumab (MK-3475) in Combination with Backbone Treatments for Subjects with Multiple Myeloma.

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell, Little Silver

Sponsor
Merck

Protocol Number
3475-023 KEYNOTE

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase I Multi-Cohort Trial of Pembrolizumab (MK-3475) in Combination with Backbone Treatments for Subjects with Multiple Myeloma.

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell, Little Silver

Sponsor
Merck

Protocol Number
3475-023 KEYNOTE

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase I Multi-Cohort Trial of Pembrolizumab (MK-3475) in Combination with Backbone Treatments for Subjects with Multiple Myeloma.

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell, Little Silver

Sponsor
Merck

Protocol Number
3475-023 KEYNOTE

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase I Multi-Cohort Trial of Pembrolizumab (MK-3475) in Combination with Backbone Treatments for Subjects with Multiple Myeloma.

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell, Little Silver

Sponsor
Merck

Protocol Number
3475-023 KEYNOTE

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase I Multi-Cohort Trial of Pembrolizumab (MK-3475) in Combination with Backbone Treatments for Subjects with Multiple Myeloma.

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell, Little Silver

Sponsor
Merck

Protocol Number
3475-023 KEYNOTE

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase I Multi-Cohort Trial of Pembrolizumab (MK-3475) in Combination with Backbone Treatments for Subjects with Multiple Myeloma.

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell, Little Silver

Sponsor
Merck

Protocol Number
3475-023 KEYNOTE

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase I Multi-Cohort Trial of Pembrolizumab (MK-3475) in Combination with Backbone Treatments for Subjects with Multiple Myeloma.

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell, Little Silver

Sponsor
Merck

Protocol Number
3475-023 KEYNOTE

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase I Multi-Cohort Trial of Pembrolizumab (MK-3475) in Combination with Backbone Treatments for Subjects with Multiple Myeloma.

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell, Little Silver

Sponsor
Merck

Protocol Number
3475-023 KEYNOTE

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase I Multi-Cohort Trial of Pembrolizumab (MK-3475) in Combination with Backbone Treatments for Subjects with Multiple Myeloma.

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell, Little Silver

Sponsor
Merck

Protocol Number
3475-023 KEYNOTE

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase I Multi-Cohort Trial of Pembrolizumab (MK-3475) in Combination with Backbone Treatments for Subjects with Multiple Myeloma.

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell, Little Silver

Sponsor
Merck

Protocol Number
3475-023 KEYNOTE

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase I Multi-Cohort Trial of Pembrolizumab (MK-3475) in Combination with Backbone Treatments for Subjects with Multiple Myeloma.

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell, Little Silver

Sponsor
Merck

Protocol Number
3475-023 KEYNOTE

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase I Multi-Cohort Trial of Pembrolizumab (MK-3475) in Combination with Backbone Treatments for Subjects with Multiple Myeloma.

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell, Little Silver

Sponsor
Merck

Protocol Number
3475-023 KEYNOTE

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase I Multi-Cohort Trial of Pembrolizumab (MK-3475) in Combination with Backbone Treatments for Subjects with Multiple Myeloma.

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell, Little Silver

Sponsor
Merck

Protocol Number
3475-023 KEYNOTE

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase I Multi-Cohort Trial of Pembrolizumab (MK-3475) in Combination with Backbone Treatments for Subjects with Multiple Myeloma.

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell, Little Silver

Sponsor
Merck

Protocol Number
3475-023 KEYNOTE

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase I Multi-Cohort Trial of Pembrolizumab (MK-3475) in Combination with Backbone Treatments for Subjects with Multiple Myeloma.

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell, Little Silver

Sponsor
Merck

Protocol Number
3475-023 KEYNOTE

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase I Multi-Cohort Trial of Pembrolizumab (MK-3475) in Combination with Backbone Treatments for Subjects with Multiple Myeloma.

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell, Little Silver

Sponsor
Merck

Protocol Number
3475-023 KEYNOTE

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase I Multi-Cohort Trial of Pembrolizumab (MK-3475) in Combination with Backbone Treatments for Subjects with Multiple Myeloma.

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell, Little Silver

Sponsor
Merck

Protocol Number
3475-023 KEYNOTE

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase I Multi-Cohort Trial of Pembrolizumab (MK-3475) in Combination with Backbone Treatments for Subjects with Multiple Myeloma.

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell, Little Silver

Sponsor
Merck

Protocol Number
3475-023 KEYNOTE

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase I Multi-Cohort Trial of Pembrolizumab (MK-3475) in Combination with Backbone Treatments for Subjects with Multiple Myeloma.

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell, Little Silver

Sponsor
Merck

Protocol Number
3475-023 KEYNOTE

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase I Multi-Cohort Trial of Pembrolizumab (MK-3475) in Combination with Backbone Treatments for Subjects with Multiple Myeloma.

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell, Little Silver

Sponsor
Merck

Protocol Number
3475-023 KEYNOTE

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase I Multi-Cohort Trial of Pembrolizumab (MK-3475) in Combination with Backbone Treatments for Subjects with Multiple Myeloma.

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell, Little Silver

Sponsor
Merck

Protocol Number
3475-023 KEYNOTE

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase I Multi-Cohort Trial of Pembrolizumab (MK-3475) in Combination with Backbone Treatments for Subjects with Multiple Myeloma.

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell, Little Silver

Sponsor
Merck

Protocol Number
3475-023 KEYNOTE

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase I Multi-Cohort Trial of Pembrolizumab (MK-3475) in Combination with Backbone Treatments for Subjects with Multiple Myeloma.

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell, Little Silver

Sponsor
Merck

Protocol Number
3475-023 KEYNOTE

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase I Multi-Cohort Trial of Pembrolizumab (MK-3475) in Combination with Backbone Treatments for Subjects with Multiple Myeloma.

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell, Little Silver

Sponsor
Merck

Protocol Number
3475-023 KEYNOTE

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase I Multi-Cohort Trial of Pembrolizumab (MK-3475) in Combination with Backbone Treatments for Subjects with Multiple Myeloma.

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell, Little Silver

Sponsor
Merck

Protocol Number
3475-023 KEYNOTE

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase I Multi-Cohort Trial of Pembrolizumab (MK-3475) in Combination with Backbone Treatments for Subjects with Multiple Myeloma.

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell, Little Silver

Sponsor
Merck

Protocol Number
3475-023 KEYNOTE

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase I Multi-Cohort Trial of Pembrolizumab (MK-3475) in Combination with Backbone Treatments for Subjects with Multiple Myeloma.

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell, Little Silver

Sponsor
Merck

Protocol Number
3475-023 KEYNOTE

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase I Multi-Cohort Trial of Pembrolizumab (MK-3475) in Combination with Backbone Treatments for Subjects with Multiple Myeloma.

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell, Little Silver

Sponsor
Merck

Protocol Number
3475-023 KEYNOTE

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase I Multi-Cohort Trial of Pembrolizumab (MK-3475) in Combination with Backbone Treatments for Subjects with Multiple Myeloma.

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell, Little Silver

Sponsor
Merck

Protocol Number
3475-023 KEYNOTE

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase I Multi-Cohort Trial of Pembrolizumab (MK-3475) in Combination with Backbone Treatments for Subjects with Multiple Myeloma.

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell, Little Silver

Sponsor
Merck

Protocol Number
3475-023 KEYNOTE

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase I Multi-Cohort Trial of Pembrolizumab (MK-3475) in Combination with Backbone Treatments for Subjects with Multiple Myeloma.

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell, Little Silver

Sponsor
Merck

Protocol Number
3475-023 KEYNOTE

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase I Multi-Cohort Trial of Pembrolizumab (MK-3475) in Combination with Backbone Treatments for Subjects with Multiple Myeloma.

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell, Little Silver

Sponsor
Merck

Protocol Number
3475-023 KEYNOTE

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase I Multi-Cohort Trial of Pembrolizumab (MK-3475) in Combination with Backbone Treatments for Subjects with Multiple Myeloma.

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell, Little Silver

Sponsor
Merck

Protocol Number
3475-023 KEYNOTE

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase I Multi-Cohort Trial of Pembrolizumab (MK-3475) in Combination with Backbone Treatments for Subjects with Multiple Myeloma.

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell, Little Silver

Sponsor
Merck

Protocol Number
3475-023 KEYNOTE

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase I Multi-Cohort Trial of Pembrolizumab (MK-3475) in Combination with Backbone Treatments for Subjects with Multiple Myeloma.

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell, Little Silver

Sponsor
Merck

Protocol Number
3475-023 KEYNOTE

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase I Multi-Cohort Trial of Pembrolizumab (MK-3475) in Combination with Backbone Treatments for Subjects with Multiple Myeloma.

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell, Little Silver

Sponsor
Merck

Protocol Number
3475-023 KEYNOTE

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase I Multi-Cohort Trial of Pembrolizumab (MK-3475) in Combination with Backbone Treatments for Subjects with Multiple Myeloma.

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell, Little Silver

Sponsor
Merck

Protocol Number
3475-023 KEYNOTE

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase I Multi-Cohort Trial of Pembrolizumab (MK-3475) in Combination with Backbone Treatments for Subjects with Multiple Myeloma.

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell, Little Silver

Sponsor
Merck

Protocol Number
3475-023 KEYNOTE

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase I Multi-Cohort Trial of Pembrolizumab (MK-3475) in Combination with Backbone Treatments for Subjects with Multiple Myeloma.

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell, Little Silver

Sponsor
Merck

Protocol Number
3475-023 KEYNOTE

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase I Multi-Cohort Trial of Pembrolizumab (MK-3475) in Combination with Backbone Treatments for Subjects with Multiple Myeloma.

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell, Little Silver

Sponsor
Merck

Protocol Number
3475-023 KEYNOTE

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase I Multi-Cohort Trial of Pembrolizumab (MK-3475) in Combination with Backbone Treatments for Subjects with Multiple Myeloma.

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell, Little Silver

Sponsor
Merck

Protocol Number
3475-023 KEYNOTE

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase I Multi-Cohort Trial of Pembrolizumab (MK-3475) in Combination with Backbone Treatments for Subjects with Multiple Myeloma.

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell, Little Silver

Sponsor
Merck

Protocol Number
3475-023 KEYNOTE

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase I Multi-Cohort Trial of Pembrolizumab (MK-3475) in Combination with Backbone Treatments for Subjects with Multiple Myeloma.

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell, Little Silver

Sponsor
Merck

Protocol Number
3475-023 KEYNOTE

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase I Multi-Cohort Trial of Pembrolizumab (MK-3475) in Combination with Backbone Treatments for Subjects with Multiple Myeloma.

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell, Little Silver

Sponsor
Merck

Protocol Number
3475-023 KEYNOTE

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase I Multi-Cohort Trial of Pembrolizumab (MK-3475) in Combination with Backbone Treatments for Subjects with Multiple Myeloma.

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell, Little Silver

Sponsor
Merck

Protocol Number
3475-023 KEYNOTE

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase I Multi-Cohort Trial of Pembrolizumab (MK-3475) in Combination with Backbone Treatments for Subjects with Multiple Myeloma.

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell, Little Silver

Sponsor
Merck

Protocol Number
3475-023 KEYNOTE

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase I Multi-Cohort Trial of Pembrolizumab (MK-3475) in Combination with Backbone Treatments for Subjects with Multiple Myeloma.

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell, Little Silver

Sponsor
Merck

Protocol Number
3475-023 KEYNOTE

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase I Multi-Cohort Trial of Pembrolizumab (MK-3475) in Combination with Backbone Treatments for Subjects with Multiple Myeloma.

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell, Little Silver

Sponsor
Merck

Protocol Number
3475-023 KEYNOTE

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase I Multi-Cohort Trial of Pembrolizumab (MK-3475) in Combination with Backbone Treatments for Subjects with Multiple Myeloma.

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell, Little Silver

Sponsor
Merck

Protocol Number
3475-023 KEYNOTE

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase I Multi-Cohort Trial of Pembrolizumab (MK-3475) in Combination with Backbone Treatments for Subjects with Multiple Myeloma.

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell, Little Silver

Sponsor
Merck

Protocol Number
3475-023 KEYNOTE

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase I Multi-Cohort Trial of Pembrolizumab (MK-3475) in Combination with Backbone Treatments for Subjects with Multiple Myeloma.

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell, Little Silver

Sponsor
Merck

Protocol Number
3475-023 KEYNOTE

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase I Multi-Cohort Trial of Pembrolizumab (MK-3475) in Combination with Backbone Treatments for Subjects with Multiple Myeloma.

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell, Little Silver

Sponsor
Merck

Protocol Number
3475-023 KEYNOTE

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase I Multi-Cohort Trial of Pembrolizumab (MK-3475) in Combination with Backbone Treatments for Subjects with Multiple Myeloma.

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell, Little Silver

Sponsor
Merck

Protocol Number
3475-023 KEYNOTE

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase I Multi-Cohort Trial of Pembrolizumab (MK-3475) in Combination with Backbone Treatments for Subjects with Multiple Myeloma.

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell, Little Silver

Sponsor
Merck

Protocol Number
3475-023 KEYNOTE

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase I Multi-Cohort Trial of Pembrolizumab (MK-3475) in Combination with Backbone Treatments for Subjects with Multiple Myeloma.

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell, Little Silver

Sponsor
Merck

Protocol Number
3475-023 KEYNOTE

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase I Multi-Cohort Trial of Pembrolizumab (MK-3475) in Combination with Backbone Treatments for Subjects with Multiple Myeloma.

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell, Little Silver

Sponsor
Merck

Protocol Number
3475-023 KEYNOTE

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase I Multi-Cohort Trial of Pembrolizumab (MK-3475) in Combination with Backbone Treatments for Subjects with Multiple Myeloma.

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell, Little Silver

Sponsor
Merck

Protocol Number
3475-023 KEYNOTE

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase I Multi-Cohort Trial of Pembrolizumab (MK-3475) in Combination with Backbone Treatments for Subjects with Multiple Myeloma.

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell, Little Silver

Sponsor
Merck

Protocol Number
3475-023 KEYNOTE

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase I Multi-Cohort Trial of Pembrolizumab (MK-3475) in Combination with Backbone Treatments for Subjects with Multiple Myeloma.

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell, Little Silver

Sponsor
Merck

Protocol Number
3475-023 KEYNOTE

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

A Phase I Multi-Cohort Trial of Pembrolizumab (MK-3475) in Combination with Backbone Treatments for Subjects with Multiple Myeloma.

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell, Little Silver

Sponsor
Merck

Protocol Number
3475-023 KEYNOTE

To Learn More Call
201-510-0910

Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
Novartis

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-208

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick, Freehold, Howell, Little Silver

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin